Foghorn Therapeutics Inc.
FHTX5.960USD
+0.180+3.11%
Market hours （ET）Quotes delayed by 15 min
337.00MMarket Cap
LossP/E TTM
More Details of Foghorn Therapeutics Inc. Company
Foghorn Therapeutics Inc. is a clinical-stage, precision therapeutics biotechnology company. The Company is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.
Foghorn Therapeutics Inc. Info
Ticker SymbolFHTX
Company nameFoghorn Therapeutics Inc
IPO dateOct 23, 2020
CEOGottschalk (Adrian)
Number of employees112
Security typeOrdinary Share
Fiscal year-endOct 23
Address500 Technology Square
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02139
Phone16175863100
Websitehttps://foghorntx.com/
Ticker SymbolFHTX
IPO dateOct 23, 2020
CEOGottschalk (Adrian)
Company Executives of Foghorn Therapeutics Inc.
Name
Name/Position
Position
Shareholding
Change
Mr. Adrian Gottschalk
Mr. Adrian Gottschalk
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
511.70K
--
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Independent Director
Independent Director
72.07K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
B. Lynne Parshall ,J.D.
B. Lynne Parshall ,J.D.
Independent Director
Independent Director
--
--
Mr. Jeff Sacher
Mr. Jeff Sacher
Interim Chief Financial Officer, Treasurer
Interim Chief Financial Officer, Treasurer
--
--
Dr. Thomas J. (Tom) Lynch, Jr., M.D.
Dr. Thomas J. (Tom) Lynch, Jr., M.D.
Independent Director
Independent Director
--
--
Dr. Adm. Balkrishan (Simba) Gill, Ph.D.
Dr. Adm. Balkrishan (Simba) Gill, Ph.D.
Independent Director
Independent Director
--
--
Dr. Douglas G. (Doug) Cole, M.D.
Dr. Douglas G. (Doug) Cole, M.D.
Independent Director
Independent Director
--
--
Dr. Alfonso Quints-Cardama, M.D.
Dr. Alfonso Quints-Cardama, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Anna Rivkin, Ph.D.
Dr. Anna Rivkin, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Adrian Gottschalk
Mr. Adrian Gottschalk
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
511.70K
--
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Independent Director
Independent Director
72.07K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
B. Lynne Parshall ,J.D.
B. Lynne Parshall ,J.D.
Independent Director
Independent Director
--
--
Mr. Jeff Sacher
Mr. Jeff Sacher
Interim Chief Financial Officer, Treasurer
Interim Chief Financial Officer, Treasurer
--
--
Dr. Thomas J. (Tom) Lynch, Jr., M.D.
Dr. Thomas J. (Tom) Lynch, Jr., M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Flagship Ventures
22.41%
Fidelity Management & Research Company LLC
9.68%
BVF Partners L.P.
9.38%
Eli Lilly and Company
7.07%
Kadoch (Cigall)
6.46%
Other
45.00%
Shareholders
Shareholders
Proportion
Flagship Ventures
22.41%
Fidelity Management & Research Company LLC
9.68%
BVF Partners L.P.
9.38%
Eli Lilly and Company
7.07%
Kadoch (Cigall)
6.46%
Other
45.00%
Shareholder Types
Shareholders
Proportion
Venture Capital
23.30%
Investment Advisor
22.47%
Hedge Fund
17.18%
Corporation
10.86%
Individual Investor
7.96%
Research Firm
4.71%
Investment Advisor/Hedge Fund
4.63%
Pension Fund
0.15%
Bank and Trust
0.08%
Other
8.67%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
164
41.10M
74.66%
--
2025Q3
169
41.10M
74.88%
-10.40K
2025Q2
170
41.10M
75.92%
+565.21K
2025Q1
173
40.55M
75.96%
-1.69M
2024Q4
167
40.40M
75.19%
+310.46K
2024Q3
173
40.09M
72.52%
+554.51K
2024Q2
167
39.52M
64.99%
+4.09M
2024Q1
168
26.53M
65.58%
-1.38M
2023Q4
166
26.27M
67.28%
-777.96K
2023Q3
171
27.10M
69.25%
+109.17K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Flagship Ventures
12.67M
22.42%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
5.53M
9.79%
-54.51K
-0.98%
Jun 30, 2025
BVF Partners L.P.
5.30M
9.38%
--
--
Jun 30, 2025
Eli Lilly and Company
4.00M
7.08%
--
--
Apr 23, 2025
Kadoch (Cigall)
3.65M
6.46%
+28.53K
+0.79%
Apr 23, 2025
Deerfield Management Company, L.P.
3.26M
5.76%
--
--
Jun 30, 2025
Raymond James & Associates, Inc.
2.37M
4.19%
+148.94K
+6.71%
Jun 30, 2025
The Klarman Family Foundation
2.14M
3.79%
--
--
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
2.04M
3.6%
+204.04K
+11.13%
Jun 30, 2025
The Vanguard Group, Inc.
1.88M
3.33%
+50.05K
+2.73%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Biotechnology ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
View more
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
iShares Micro-Cap ETF
Proportion0.03%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Foghorn Therapeutics Inc.?
The top five shareholders of Foghorn Therapeutics Inc. are:
Flagship Ventures holds 12.67M shares, accounting for 22.42% of the total shares.
Fidelity Management & Research Company LLC holds 5.53M shares, accounting for 9.79% of the total shares.
BVF Partners L.P. holds 5.30M shares, accounting for 9.38% of the total shares.
Eli Lilly and Company holds 4.00M shares, accounting for 7.08% of the total shares.
Kadoch (Cigall) holds 3.65M shares, accounting for 6.46% of the total shares.
Flagship Ventures holds 12.67M shares, accounting for 22.42% of the total shares.
Fidelity Management & Research Company LLC holds 5.53M shares, accounting for 9.79% of the total shares.
BVF Partners L.P. holds 5.30M shares, accounting for 9.38% of the total shares.
Eli Lilly and Company holds 4.00M shares, accounting for 7.08% of the total shares.
Kadoch (Cigall) holds 3.65M shares, accounting for 6.46% of the total shares.
What are the top three shareholder types of Foghorn Therapeutics Inc.?
The top three shareholder types of Foghorn Therapeutics Inc. are:
Flagship Ventures
Fidelity Management & Research Company LLC
BVF Partners L.P.
Flagship Ventures
Fidelity Management & Research Company LLC
BVF Partners L.P.
How many institutions hold shares of Foghorn Therapeutics Inc. (FHTX)?
As of 2025Q4, 164 institutions hold shares of Foghorn Therapeutics Inc., with a combined market value of approximately 41.10M, accounting for 74.66% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.22%.
What is the biggest source of revenue for Foghorn Therapeutics Inc.?
In --, the -- business generated the highest revenue for Foghorn Therapeutics Inc., amounting to -- and accounting for --% of total revenue.
